Management of Heart Failure with Hypotension, Hyperkalemia, and Renal Dysfunction

Rationale for Continuing Beta-Blockers

• The American Heart Association recommends that beta-blockers should not be discontinued in heart failure patients with hypotension unless symptomatic, as they reduce mortality in heart failure patients with reduced ejection fraction 1, 2, 3
• The European Society of Cardiology states that asymptomatic hypotension does not require any change in beta-blocker therapy, and abrupt discontinuation of beta-blockers risks rebound myocardial ischemia, infarction, and arrhythmias 2, 3, 4

Managing Hyperkalemia

• The American College of Cardiology recommends that spironolactone should not be added in patients with hyperkalemia (K+ >5.0 mEq/L) and rising creatinine, as it can cause life-threatening hyperkalemia 1
• The European Society of Cardiology states that spironolactone requires potassium <5.0 mEq/L and creatinine ≤2.5 mg/dL in men before initiation, and adding spironolactone with current hyperkalemia would be potentially harmful 1

Benefits of SGLT2 Inhibitors

• The American Diabetes Association recommends that SGLT2 inhibitors improve outcomes in heart failure with reduced ejection fraction, and have favorable effects on volume status, renal function, and do not worsen hyperkalemia 1
• The European Association for the Study of Diabetes states that SGLT2 inhibitors reduce heart failure hospitalizations and cardiovascular mortality, and can be safely initiated even with mild renal impairment (creatinine 1.40 mg/dL) 1

Importance of Diuretics

• The American Heart Association recommends that IV diuresis should be maintained in patients with clear volume overload, and decreasing diuretics would worsen the patient's volume overload and heart failure symptoms 2, 6
• The European Society of Cardiology states that if worsening symptoms occur during beta-blocker therapy, the correct approach is to increase diuretics, not decrease them 2, 3

Critical Management Sequence

• The American College of Cardiology recommends the following algorithmic approach: continue carvedilol, maintain IV diuresis, keep lisinopril held, add SGLT2 inhibitor, and monitor potassium and creatinine closely 1, 2, 3

Common Pitfalls to Avoid

• The European Society of Cardiology warns that never discontinuing beta-blockers for asymptomatic hypotension is a frequent error that increases mortality risk, and do not add spironolactone with K+ >5.0 mEq/L, as it causes life-threatening hyperkalemia 1, 2, 3